Work

Table 1 from Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors

Year: 2025

Type: other

Abstract: Demographic and clinical characteristics at baseline (n = 64).

DOI: 10.1158/1078-0432.28606255

Authors: Apostolia M. Tsimberidou, David J. Vining, Sukeshi P. Arora, Sofia de Achaval, Jeffrey Larson, John Kauh, Carrie Cartwright, Rony Avritscher, Imran Alibhai, David J. Tweardy, Ahmed O. Kaseb

Language: English

Topic: Cytokine Signaling Pathways and Interactions

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4408537610

Cites:

Cited by: 1

Related to: 10